ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      58,748.50
      1.48%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Lexicon Pharmaceuticals Inc (LXRX)

      7. Lexicon Pharmaceuticals Inc (LXRX) News

      LXRX

      Lexicon Pharmaceuticals (LXRX)

      Lexicon Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:LXRX
      DateTimeSourceHeadlineSymbolCompany
      03/03/20177:00AMPR Newswire (US)Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Fourth Quarter And Full Year Financial ResultsNASDAQ:LXRXLexicon Pharmaceuticals Inc
      03/01/20176:54PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      03/01/20176:53PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      03/01/20176:52PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      03/01/20176:51PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      03/01/20176:50PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      03/01/20176:49PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      03/01/20174:39PMPR Newswire (US)Lexicon To Report Fourth Quarter And Year End 2016 Financial Results On March 3, 2017NASDAQ:LXRXLexicon Pharmaceuticals Inc
      02/28/20173:56PMPR Newswire (US)FDA Approves Lexicon Drug XERMELO™ (telotristat ethyl) 250 mg As First And Only Oral Treatment For Carcinoid Syndrome Diarr...NASDAQ:LXRXLexicon Pharmaceuticals Inc
      02/15/20174:27PMEdgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      02/14/201711:34AMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      02/13/20174:34PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      02/13/20174:31PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      02/13/20174:29PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      02/13/20174:29PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      02/13/20174:28PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      02/13/20174:27PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      02/13/20174:27PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      02/13/20174:01PMPR Newswire (US)Lexicon To Present At The Leerink Partners 6th Annual Global Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
      01/20/20173:47PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      01/09/20178:00AMPR Newswire (US)Lexicon Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of DiabetesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      01/05/20174:30PMPR Newswire (US)Lexicon To Present At The 35th Annual J.P. Morgan Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
      12/21/20166:45AMPR Newswire (US)Lexicon Reports Positive Top-line Results In Second Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 DiabetesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      12/20/20162:06PMEdgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      12/05/20164:01PMPR Newswire (US)Lexicon Reports Top-Line Results From Phase 2 Clinical Trial Conducted In Collaboration With JDRFNASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/22/20164:36PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/21/20167:00AMPR Newswire (US)Lexicon Announces The Establishment Of The Commercial Leadership Team For Telotristat EthylNASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/14/20167:00AMPR Newswire (US)Lexicon To Present At The Stifel 2016 Healthcare Conference And The Jefferies 2016 Global Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/07/20164:53PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/07/20168:52AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LXRXLexicon Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:LXRX